Skip to main content
SYK logo

Stryker Corporation (SYK) Stock: Price, Forecast & Analyst Target

Stryker Corporation (SYK) — MoonshotScore 80/100 (Exceptional band), calculated Nov 18, 2026. Price $318.15 (+0.19%), as of the Nov 18, 2026 trading session; market cap $121B. Expected results Feb 4, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$318.15 +$0.61 (+0.19%) Market Cap $121B

Stryker Corporation · SYK · NYSE · Healthcare · Medical - Devices

Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): Stryker sells orthopedic implants, surgical equipment, neurovascular devices, patient-handling systems and recurring-use hospital products rather than relying on a narrow implant franchise. The case depends on whether procedure demand and hospital capital spending can keep lifting revenue while cash generation absorbs a debt load that materially exceeds liquid resources.

Price as of Nov 18, 2026

Key Statistics

80 of 100

MoonshotScore v2 · Stryker (SYK)

Exceptional
Business Quality Elite (88)
Financial Safety Okay (56)
Valuation Full (47)
Growth Durability Compounding (86)
Momentum Rising (73)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.

  • quarterly revenue $6.52B (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 6 of the last 8 reports
  • expected results Feb 4, 2027

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SYK (57 recorded, newest six shown)
RecordedScoreBand
80Exceptional
80Exceptional
80Exceptional
80Exceptional
80Strong
80Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$318.15
Change on the day+0.19%
52-week range$267.00–$389.33
Market capitalisation$121B—
Price / earnings (trailing)33.60
Shares traded on the day3.25M
Beta (volatility vs the S&P 500)0.78

Why Stryker scores 80

Dr. Mira Sol, the Stock Expert AI TV data character
Business Quality carries the score; Valuation is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
80Exceptional
  • Business Quality88
  • Financial Safety56
  • Valuation47
  • Growth Durability86
  • Momentum73

Share price, last 12 months -17.1%

$373.42 $309.64

What the price assumes

10.6% a year of free-cash-flow growth for ten years is what a $117.88B market value ( snapshot) asks for.

  • Price implies, next ten years10.6%
  • Free cash flow, last 5 years9.0%
  • Revenue, last 5 years11.8%
  • Analysts' revenue path, 2026–20307.1%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $4.57B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 9 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 4.0% either way.

  1. +6.7%Jan ’24
  2. -3.2%Apr ’24
  3. -1.7%Jul ’24
  4. +2.1%Oct ’24
  5. -2.2%Jan ’25
  6. +1.1%May ’25
  7. -5.6%Jul ’25
  8. -3.6%Oct ’25
  9. +3.3%Jan ’26
  10. -6.5%Apr ’26
  11. -7.5%Jul ’26
  12. -4.0%Oct ’26
Next-session move EPS beat (9) EPS in line (2) EPS miss (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
In lineMiss-4.0%+10.2%
BeatIn line-7.5%-4.2%
MissMiss-6.5%-6.6%
BeatIn line+3.3%+1.3%
BeatIn line-3.6%-4.3%
BeatBeat-5.6%-6.0%
BeatBeat+1.1%+2.3%
BeatBeat-2.2%-1.9%
BeatBeat+2.1%+3.9%
In lineIn line-1.7%-3.2%
BeatBeat-3.2%-2.0%
BeatBeat+6.7%+8.0%

Beating the estimate has not been enough: the stock fell after 5 of the last 9 beats. The bar it has to clear is the whisper number, not the published one.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “against strong”, “knee market” — none of them came up in Q2 FY2026.
  • Gone quiet: “full commercial”, “organic growth”, “capital products” — regular themes last call, absent this time.

The tone held steady from one call to the next; what changed is the subject matter, not the confidence.

Our track record on this stock

Since the score went from 79 to 80 while the share price moved -2.9% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range
Band changes, newest first. “Right” means the price moved the way the change pointed over the next three months.
DateBand3 months6 monthsCall
Exceptional → Strong———
Strong → Exceptional———
Exceptional → Strong———
Strong → Exceptional———

None of the 4 band changes we have recorded has been graded yet; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 69% of 52 rate it a buy; the average target sits +12.1% from the price of $318.15.
  • Last 90 days: 0 upgrades and 1 downgrade among 20 rating actions.
  • Our signals: Exceptional band; strongest pillar Business Quality (88), weakest Valuation (47).

Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $272, high $387, latest $318. 4 reported quarters marked, 2 above and 2 below the recorded estimate. $387 $272 high $387 Jan 29, 2026 · Earnings results · reported above the recorded estimate · close $3701Apr 30, 2026 · Earnings results · reported below the recorded estimate · close $2952Jul 30, 2026 · Earnings results · reported above the recorded estimate · close $3263Oct 29, 2026 · Earnings results · reported below the recorded estimate · close $2924 Oct 17, 2025 Nov 18, 2026 · $318 $374Oct 17, 2025$356Oct 31, 2025$362Nov 14, 2025$371Nov 28, 2025$354Dec 12, 2025$354Dec 26, 2025$368Jan 9, 2026$355Jan 23, 2026$358Feb 6, 2026$380Feb 20, 2026$365Mar 6, 2026$336Mar 20, 2026$332Apr 2, 2026$343Apr 17, 2026$295May 1, 2026$307May 15, 2026$305May 29, 2026$312Jun 12, 2026$333Jun 26, 2026$330Jul 10, 2026$330Jul 24, 2026$339Aug 7, 2026$329Aug 21, 2026$303Sep 4, 2026$275Sep 18, 2026$275Oct 2, 2026$295Oct 16, 2026$292Oct 30, 2026$310Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Stryker (SYK): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Revenue Growth Moderate

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Stryker (SYK), and what does it report?

Short answer · as of

Hospitals and medical professionals buy Stryker products for joint replacement, trauma, spine, surgery, emergency care, patient handling and neurovascular treatment.

Demand therefore comes from procedures, equipment purchases and consumption of disposable or reprocessed devices, with company subsidiaries and distributors carrying the portfolio across international markets.

Stryker is not primarily a hip-and-knee implant company. MedSurg and Neurotechnology contributes more revenue than Orthopaedics, so reported sales blend implant demand with hospital capital purchases, surgical workflows, emergency care and recurring-use products.

2 · Latest results

What do the latest results show for Stryker (SYK)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $6.52B.

The latest quarter delivered higher revenue, gross profit, operating profit, net income and diluted earnings than the comparable period. It also marked a sharp recovery from the preceding quarter, when revenue and earnings fell short of expectations; the latest release moved revenue back above expectations and earnings comfortably ahead.

Across the annual series, revenue advanced throughout the reported span while research spending also rose. Net income followed a less even path, which makes operating leverage and expense control important alongside sales growth.

Management attributes the outlook to acute and emergent procedure exposure, durable demand for capital products, modestly favorable pricing and a potentially helpful currency effect. Those are management’s stated supports; the reported improvement itself is visible in revenue, profit and cash flow.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$6.52B Oct 29, 2026
Latest report · revenue estimate
$6.62B Oct 29, 2026
Latest report · revenue vs estimate
Below estimate Oct 29, 2026
Latest report · EPS vs estimate
Below estimate Oct 29, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 29, 2026$6.52B$6.62B$3.5200$3.5500
Jul 30, 2026$6.59B$6.58B$3.6900$3.4900
Apr 30, 2026$6.02B$6.34B$2.6000$2.9800
Jan 29, 2026$7.17B$7.12B$4.4700$4.4000
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$6.52B$753M$1.96 (diluted)
Q2 FY2026$6.59B$1.28B$3.31 (diluted)
Q1 FY2026$6.02B$745M$1.93 (diluted)
Q4 FY2025$7.17B$849M$2.20 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Stryker (SYK)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Stryker generates substantial operating cash flow after capital spending, and the latest quarter improved markedly from the preceding period. Liquidity ratios indicate near-term obligations are covered, while the quality and distress screens remain supportive.

The balance sheet is not cash rich relative to borrowings: total debt stands well above cash and investments, leaving the company in a net-debt position. Cash has recovered from the preceding quarter but remains below the opening level of the reported history, so repurchases compete with debt reduction and other uses of capital.

A downturn in procedure activity would pressure implant and intervention products, while weaker hospital capital budgets would affect equipment demand. The broad portfolio spreads exposure across clinical categories, but much of it still depends on healthcare institutions continuing procedures and purchasing systems.

4 · What to check next?

What should you watch next at Stryker (SYK)?

Short answer · as of

The next earnings report is expected on Feb 4, 2027.

Watch whether revenue and operating profit sustain the latest rebound rather than reverting toward the preceding quarter’s weaker result. The scheduled earnings release offers the clearest near-term check, while analyst estimates assume continued expansion in revenue and earnings across the forecast horizon.

Organic sales growth, capital-product demand, pricing and currency are the operating markers management has identified. Cash conversion deserves equal attention because management plans to resume repurchases even as debt remains materially above cash and investments.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Stryker compare with its peers?

Short answer

Stryker's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Stryker combines orthopedic implants with surgical equipment, navigation, endoscopy, patient handling, emergency care, neurovascular devices, biosurgery products and device reprocessing. That breadth creates a different demand mix from a pure implant manufacturer or a stand-alone capital-equipment vendor.

MedSurg and Neurotechnology is the larger reported business, while Orthopaedics supplies the implant and trauma exposure commonly associated with the company. Acute and emergent procedures can support demand when discretionary procedures soften, although hospital purchasing remains a shared link across much of the portfolio.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Edwards Lifesciences Corporation (EW) Same industry, near in market value$105.23 Nov 18, 2026$60.5B93 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Same industry, near in market value$80.19 Nov 19, 2026$29.9B93 5-pillar Nov 18, 2026
Sanofi (SNY) Named competitor$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
STERIS plc (STE) Same industry, near in market value$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Medtronic plc (MDT) Same industry, near in market value$100.72 Nov 18, 2026$129B81 5-pillar Nov 18, 2026
Stryker (SYK) — this page$318.15$121B80
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$103.32 Nov 18, 2026$19.6B79 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
Boston Scientific Corporation (BSX) Same industry, near in market value$43.64 Nov 18, 2026$63.3B77 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Danaher Corporation (DHR) Named competitor$228.58 Nov 18, 2026$161B71 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$309.00 – $407.00
Consensus target
$356.69
Median target
$364.50

Consensus record · Captured .

Measured against a quoted price of $318.15 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026

Transactions
48
Identified insiders
8
Purchases
0
Sales
40
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SYK in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
FundsmithTerry SmithQ3 20265.70%$735.98MTrimmed −8.3% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Stryker (SYK)?

Read these with our analysis →

What Investors Ask About Stryker (SYK) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

Is Stryker mainly a hip-and-knee implant company?

MedSurg and Neurotechnology contributes more revenue than Orthopaedics. Joint replacement remains important, but surgical equipment, emergency care, patient handling, neurovascular products and recurring-use devices make Stryker a broader hospital supplier.

How do Stryker capital products affect its revenue profile?

Capital products tie part of revenue to hospital equipment purchasing rather than procedure volume alone. Management describes demand for those products as durable, making order momentum an important test of the outlook.

Why does Stryker’s MedSurg and Neurotechnology mix matter?

The segment carries the larger share of company revenue and spans surgical equipment, patient handling, emergency care and neurotechnology. Its scale means Stryker’s results cannot be read solely through orthopedic procedure trends.

Can Stryker fund resumed share repurchases while carrying debt?

Operating cash generation provides capacity for repurchases, and management has announced plans to resume them. Debt nevertheless exceeds cash and investments by a wide margin, so subsequent cash conversion and balance-sheet movement will show the trade-off.

What is the SYK stock price today?

The last price recorded for Stryker Corporation (SYK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SYK price target?

The analyst consensus price target for Stryker Corporation (SYK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 43 figures on this page — 1 from SEC filings and earnings calls, 36 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Revenue by segment; Cash, investments and debt; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 1. What is Stryker (SYK), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment
  • 2. What do the latest results show for Stryker (SYK)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Stryker (SYK)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Business description
  • 4. What should you watch next at Stryker (SYK)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions)
  • 5. How does Stryker compare with its peers?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: Is Stryker mainly a hip-and-knee implant company?: Business description; Revenue by segment
  • FAQ: How do Stryker capital products affect its revenue profile?: Business description; Management outlook — dated call excerpts
  • FAQ: Why does Stryker’s MedSurg and Neurotechnology mix matter?: Revenue by segment; Business description
  • FAQ: Can Stryker fund resumed share repurchases while carrying debt?: Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold SYK

Funds in our ETF coverage that list SYK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Jensen Quality Growth ETF (JGRW)4.20%